T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive malignant hematological
disorder arising in the thymus from T-cell progenitors. T-ALL mainly affects children and …

Abstract Selective phosphoinositide 3-kinase (PI3K)/AKT/mTOR inhibitors are currently
under evaluation in clinical studies. To identify tumor types that are sensitive to PI3K …

T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive malignant disorder arising
within the thymus from the clonal proliferation of T-cell precursors. T-ALL accounts for 25 …

Although significant improvements have been made in the treatment of acute lymphoblastic
leukemia (ALL), there is a substantial subset of high-risk T-cell ALL (T-ALL) patients with …

T-cell acute lymphoblastic leukemia (T-ALL) is a heterogeneous neoplastic disorder of
immature hematopoietic precursors committed to the T-cell lineage. T-ALL comprises about …

Purpose Aberrant PI3K/AKT/mTOR signaling has been linked to oncogenesis and therapy
resistance in various malignancies including leukemias. In Philadelphia chromosome (Ph) …

Recent findings have highlighted that constitutively active phosphatidylinositol 3-kinase
(PI3K)/Akt/mammalian target of rapamycin (mTOR) signaling is a common feature of T-cell …

Recent investigations have documented that constitutively activated phosphatidylinositol 3-
kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) signaling is a common feature of …

The major regulators of human acute lymphoblastic leukemia (ALL) cell growth and survival
mediate their effects through the phosphoinositide 3-kinase (PI-3K)/mammalian target of …

An attractive molecular target for novel anti-cancer therapies is the phosphatidylinositol 3-
kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway which is commonly …